Compositions and methods for the prevention and treatment of Huntington's disease
First Claim
1. An oligonucleotide for targeted alteration of the genetic sequence of the Huntington'"'"'s disease gene, comprising a single-stranded oligonucleotide having a DNA domain, said DNA domain having at least one mismatch with respect to the genetic sequence of the Huntington'"'"'s disease gene to be altered, and further comprising chemical modifications of the oligonucleotide, said chemical modifications selected from the group consisting of an O-methyl modification, an LNA modification including LNA derivatives and analogs, two or more phosphorothioate linkages on one or more termini, and a combination of any two or more of these modifications.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides compositions and methods for the prevention and treatment of a neurodegenerative disease, specifically Huntington'"'"'s disease. In particular, the invention provides single-stranded, modified oligonucleotides for the targeted alteration of the genetic sequence of the Huntington'"'"'s disease gene, and mehods of treating or preventing Huntington'"'"'s disease using the same.
196 Citations
35 Claims
- 1. An oligonucleotide for targeted alteration of the genetic sequence of the Huntington'"'"'s disease gene, comprising a single-stranded oligonucleotide having a DNA domain, said DNA domain having at least one mismatch with respect to the genetic sequence of the Huntington'"'"'s disease gene to be altered, and further comprising chemical modifications of the oligonucleotide, said chemical modifications selected from the group consisting of an O-methyl modification, an LNA modification including LNA derivatives and analogs, two or more phosphorothioate linkages on one or more termini, and a combination of any two or more of these modifications.
-
8. An oligonucleotide for targeted alteration of the genetic sequence of the Huntington'"'"'s disease gene, comprising a chimeric RNA/DNA oligonucleotide, said oligonucleotide having at least one mismatch with respect to the genetic sequence of the Huntington'"'"'s disease gene to be altered.
- 19. A method of treating Huntington'"'"'s disease, comprising administering to a subject an effective amount of an oligonucleotide, wherein said oligonucleotide comprises a single-stranded oligonucleotide having a DNA domain, said DNA domain does or does not hybridize to the genetic sequence of the Huntington'"'"'s disease gene, and further comprises chemical modifications of the oligonucleotide, said chemical modifications being selected from the group consisting of an o-methyl modification, an LNA modification including LNA derivatives and analogs, one or more phosphorothioate linkages on one or more termini, and a combination of any two or more of these modifications.
-
20. A method of preventing Huntington'"'"'s disease, comprising the step of administering to a subject an effective amount of an oligonucleotide, wherein said oligonucleotide comprises a single-stranded oligonucleotide having a DNA domain, said DNA domain does or does not hybridize to the genetic sequence of the Huntington'"'"'s disease gene, and further comprises chemical modifications of the oligonucleotide, said chemical modifications being selected from the group consisting of an o-methyl modification, an LNA modification including LNA derivatives and analogs, one or more phosphorothioate linkages on one or more termini, and a combination of any two or more of these modifications.
-
21. A method of reducing Huntingtin comprising protein aggregates in cells, said protein aggregates being a characteristic of Huntington'"'"'s disease, comprising the step of administering to a subject an effective amount of an oligonucleotide, wherein said oligonucleotide comprises a single-stranded oligonucleotide having a DNA domain, said DNA domain does or does not hybridize to the genetic sequence of the Huntington'"'"'s disease gene, and further comprises chemical modifications of the oligonucleotide, said chemical modifications being selected from the group consisting of an o-methyl modification, an LNA modification including LNA derivatives and analogs, one or more phosphorothioate linkages on one or more termini, and a combination of any two or more of these modifications.
-
22. A method of inhibiting the formation of Huntingtin comprising protein aggregates in cells, said protein aggregates being a characteristic of Huntington'"'"'s disease, comprising the step of administering to a subject an effective amount of an oligonucleotide, wherein said oligonucleotide comprises a single-stranded oligonucleotide having a DNA domain, said DNA domain does or does not hybridize to the genetic sequence of the Huntington'"'"'s disease gene, and further comprises chemical modifications of the oligonucleotide, said chemical modifications being selected from the group consisting of an o-methyl modification, an LNA modification including LNA derivatives and analogs, one or more phosphorothioate linkages on a terminus, and a combination of any two or more of these modifications.
Specification